Clinical Trial Update: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Allo-RevCAR01-T-CD123 in CD123-positive hematologic malignancies, including relapsed or refractory acute myeloid leukemia, is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allo-RevCAR01-T-CD123

Snippet

Sponsor: AvenCell Europe GmbH | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Status: RECRUITING